[1]崔蕾?? 郭延丽卫培峰 朱丽红.妇可靖胶囊治疗慢性盆腔炎大鼠疗效 及其作用机制研究?[J].陕西中医药大学学报,2021,44(03):069-74.[doi:10.13424/j.cnki.jsctcm.2021.03.016]
　CUI Lei GUO Yanli WEI Peifeng ZHU Lihong.Effects of Fukejing Capsule on Chronic Pelvic Inflammatory Rats and Its Mechanism[J].Journal of Shaanxi University of Traditional Chinese Medicine,2021,44(03):069-74.[doi:10.13424/j.cnki.jsctcm.2021.03.016]
点击复制

妇可靖胶囊治疗慢性盆腔炎大鼠疗效 及其作用机制研究?
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
44
期数:
2021年03期
页码:
069-74
栏目:
出版日期:
2021-05-30

文章信息/Info

Title:
Effects of Fukejing Capsule on Chronic Pelvic Inflammatory Rats and Its Mechanism
文章编号:
2096-1340(2021)03-0069-05
作者:
崔蕾1?? 郭延丽2卫培峰2 朱丽红1
1. 咸阳市中心医院,陕西 咸阳 712000;
2. 陕西中医药大学,陕西 咸阳 712046;
3. 陕西中医药大学第二附属医院,陕西 咸阳 712000
Author(s):
CUI Lei1 GUO Yanli2 WEI Peifeng2 ZHU Lihong1
1. Xianyang Central Hospital, Shaanxi Xianyang 712000,China;
2. Shaanxi University of Traditional Chinese Medicine, Shaanxi Xianyang 712046,China;
3. The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine; Shaanxi X
关键词:
妇可靖胶囊; CPID; 1L-1β; TNF-α; FGF-2; IGF-1
Keywords:
Fukejing capsule (FKJC);  CPID;  1L-1 β;  TNF-α;  FGF-2;  IGF-1
分类号:
R734
DOI:
10.13424/j.cnki.jsctcm.2021.03.016
文献标志码:
A
摘要:
目的 通过妇可靖胶囊(FKJC)干预慢性盆腔炎( chronic pelvic inflammatory disease, CPID) 模型大 鼠,观察 FKJC 对 CPID 大鼠的治疗作用,并从形态学、病理学、分子生物学层面,对其可能的作用机制进行初步 探讨,为 FKJC 的临床推广应用提供理论依据。 方法 65 只 SD 雌性大鼠随机抽取 10 只为空白对照组,造模 15 d 后随机抽取 5 只模型大鼠进行形态学和病理学观察用于模型验证,造模成功后,随机分为模型组( n = 10)、坤复 康胶囊组(n = 10)、FKJC 低、中、高剂量组(n = 10)。 空白对照组和模型组灌服蒸馏水,其余各组分别灌胃给药, 1 次/ d,持续 28d。 每天观察大鼠情况,每 7d 测量大鼠体重。 末次给药后,禁食不禁水 12 h,处理动物。 腹主动 脉中收集血液,切除子宫组织。 ELASA 法检测血清中 1L-1β 和 TNF-α 水平,蛋白免疫印迹(WB)法检测子宫组 织中 FGF-2、IGF-1 蛋白表达水平。 结果 造模 15 d 后模型大鼠的观察结果符合 CPID 病理特征,表明模型建立成 功。 治疗后,各治疗组血清中 1L-1β 及 TNF-α 的含量相比于模型组均下降( p < 0. 05)。 子宫大体形态观察,模 型组宫腔缩小,子宫内膜充血,骨盆黏连;各治疗组均较模型组有所好转。 WB 蛋白表达趋势显示模型组子宫组 织 FGF-2、IGF-1 蛋白表达增加,经药物干预后, FKJC 高、中剂量组 FGF-2、IGF-1 的蛋白表达量较模型组减少( p < 0. 05),且这种变化趋势在 FKJC 各剂量组表现出剂量依赖性,剂量越大,变化越明显。 结论 FKJC 可以明显改 善慢性盆腔炎大鼠病理症状,这可能与其抑制炎性介质 1L-1β 和 TNF-α 的释放及下调子宫 FGF-2、IGF-1 的蛋白 表达有着密切的关系。
Abstract:
Objective To observe the therapeutic effect of Fukejing Capsule(FKJC) on the rats with chronic pelvic inflammatory disease (CPID) , and to explore the possible mechanism of FKJC from the aspects of morphology, pathology and molecular biology, and provide theoretical basis for the clinical application of FKJC. Methods 65 SD female rats were randomly divided into blank control group (sham operation group, n = 10). After 15 days of model making, 5 rats were randomly selected for morphological and pathological observation for model verification. After the model was successfully established, they were randomly divided into model group (n = 10), Kunfukang capsule group (n = 10), FKJC low, me- dium and high dose group (n = 10). The blank control group and model group were given distilled water, and the rest groups were given the medicine once a day for 28 days. Observe the rat every day and measure the weight every 7 days. Blood was collected from abdominal aorta and uterus was removed. The levels of 1L-1 β and TNF-α in serum were detec- ted by ELISA, and the expression levels of FGF-2 and IGF-1 in uterus were detected by Western blot (WB). Results The results of the model rats were in accordance with the pathological characteristics of CPID 15 days after the model was established, which indicated that the model was successfully established. After the treatment, the levels of 1L-1 β and TNF-α in serum of each treatment group were lower than those in the model group (p < 0. 05). The uterus morphology was observed, the uterine cavity in the model group was reduced, the endometrium was congested and the pelvis was atta- ched. After administration, the treatment group was better than the model group. WB protein expression trend showed that the expression of FGF-2 and IGF-1 in uterus tissue of model group increased. After the intervention of drug, the protein expression of FGF-2 and IGF-1 in FKJC high and medium dose group was lower than that in model group ( p < 0. 05). The change trend showed dose dependence in FKJC dose group, the greater the dose, the more obvious the change. Con- clusion FKJC can improve the pathological symptoms of chronic pelvic inflammatory rats. It may be closely related to the inhibition of the release of inflammatory media 1L-1 β and TNF-α and down regulation of the expression of FGF-2 and IGF-1 in uterus.

参考文献/References:

[1]马云. 菝葜治疗慢性盆腔炎的活性部位筛选及作用机 制研究[D]. 广州:南方医科大学,2013.
[2]刘素香. 妇可靖胶囊对盆腔炎患者血清中转化生长因 子 - β 和血管细胞黏附分子 - 1 和氧自由基水平的影 响[J]. 中国卫生检验杂志,2017,27(22):3257-3259.
[3]赵诗韵. 慢性盆腔炎患者的不同中医证型与生存质量 的相关性研究[D]. 广州:广州中医药大学,2013.
[4]The development and efficacy of an interdisciplinary chro- nic pelvic pain program. [ J]. Canadian Urological Asso- ciation journal = Journal de l’Association des urologues du Canada,2020.
[5]陈海霞,谷晓芬,刘雁峰. 慢性盆腔炎的中医药治疗概 况[J]. 北京中医药大学学报(中医临床版),2013,20 (5);40-43.
[6]王永炎. 中成药临床应用指南感染性疾病分册[M]. 北京:中国中医药出版社,2015:161.
[7]陈振连. 妇可靖胶囊联合奥硝唑分散片治疗慢性盆腔 炎的临床研究[ J]. 现代药物与临床,2017,32 (2); 307-310.
[8]陈明. 中药治疗慢性盆腔炎的药效学实验研究概述 [J]. 中医药临床杂志,2008(2):202-204.
[9]段成兵. 病理 HE 染色制片技术的探讨[J]. 世界最新 医学信息文摘,2015,15(8):137.
[10]吕耀中,宗绍波,李芳,等. 散结镇痛胶囊对慢性盆腔 炎大鼠抗炎及抗纤维化研究[ J]. 中草药,2019,50 (20):5011-5017.
[11]秦翠梅,于洪建,陈建梅,等. 三棱 - 莪术有效组分配 伍液对慢性盆腔炎大鼠盆腔粘连的影响[J]. 中成药, 2018,40(6):1233-1237.
[12]黄露. 奥硝唑分散片联合妇可靖胶囊对慢性盆腔炎 患者炎性因子及免疫功能的影响[ J]. 医学理论与实 践,2019,32(5):713-715.
[13]吴碧辉,冷嫦娥,蒋贵林. 支原体感染与输卵管性不 孕之间的研究进展[J]. 中国民康医学,2011,23(13): 1654-1655.
[14]朱兰,赵煜,刘军,等. 慢性盆腔炎国内外的研究现状 [J]. 西南国防医药,2007,(3):376-378.
[15] 宫雪梅. 盆腔炎症性疾病的研究进展[ J]. 中国麻风 皮肤病杂志,2003,(5):473-475.
[16]张嘉晔. 坤复康胶囊对盆腔炎性疾病后遗症红细胞 免疫影响[D]. 广州:广州中医药大学,2017.
[17]周玉海. 中医药治疗慢性盆腔炎的临床研究进展 [J]. 湖南中医药导报,2002(6):316-317.
[18] 高冲,刘璐,胡爱菊,等. 活血化瘀中药的药理作用研 宄进展[J]. 药物评价研究,2013,36(1):64-68.
[19]李瑞奇,白明,苗明三. 清热药的特点及现代研究 [J]. 中医学报,2013,28(7):1003-1005.
[20] 黄灵霞. 妇可靖胶囊联合头孢替唑钠与替硝唑治疗 急性盆腔炎患者的临床效果分析[ J]. 中国药物经济 学,2018,13(8):88-90.
[21] 舒琪,杨雅荣,马辉平. 妇可靖胶囊治疗慢性盆腔炎 患者的效果及对免疫功能、氧自由基水平的影响[ J].
[22] 曾薇薇,姚吉龙,李军. 胰岛素样生长因子 - 1 和转 化生长因子-β-1 在宫腔粘连患者子宫内膜表达的研 究[J]. 广西医学,2015,37(4):470-472.
[23] 陈龙,王文华,朱胜强,等. 川芎嗪对大鼠脑缺血再灌 注后 1L - 1β 和 ICAM - 1 表达的影响[ J]. 临床医药 实践,2009,18(24):561-562.
[24] 杨静. 甲连盆腔胶囊对盆腔炎性疾病后遗症模型大 鼠 sICAM-1、 FGF-2 及 TGF-β1 / Smads 通 路 的 影 响 [D]. 泸州:西南医科大学,2020.
[25] 李丽华. 血清中 IGF - 1 及 PI3K/ Akt 信号通路在 P- COS 患者体内表达的变化及意义[ J]. 实验与检验医 学,2018,36(3):333-336

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目(81303243)
更新日期/Last Update: 2021-06-08